Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system

World Journal of Gastroenterology

Volumn 9, Issue 12, 2003, Pages 2671-2675

  Wang, Xiao Zhong ^a   Chen, Xiao Chun ^a   Chen, Yun Xin ^a   Zhang, Li Juan ^a   Li, Dan ^a   Chen, Feng Lin ^a   Chen, Zhi Xin ^a   Chen, Hong Ying ^a   Tao, Qi Ming ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; FASL PROTEIN; HEPATITIS B ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS X PROTEIN; HEPATITIS B X PROTEIN; HEPATITIS B(E) ANTIGEN; MEMBRANE PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETICS; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TUMOR; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZATION; REFERENCE VALUE; SEQUENCE ANALYSIS; STAINING; STATISTICAL ANALYSIS; VIROLOGY;

EID: 0346337113     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i12.2671     Document Type: Article

References (42)

1. Koike K, Tsutsumi T, Fujie H, Shintani Y, Moriya K. Molecular mechanism of viral hepatocarcinogenesis. Oncology 2002; 62 (Suppl 1): 29-37
2. Tang ZY. Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445-454
3. Wang WL, Gu GY, Hu M. Expression and significance of HBV genes and their antigens in human primary intrahepatic cholangiocarcinoma. World J Gastroenterol 1998; 4: 392-396
4. Yeh CT. Hepatitis B virus X protein: Searching for a role in hepatocarcinogenesis. J Gastroenterol Hepatol 2000; 15: 339-341
5. Lian ZR, Liu J, Pan JB, Tufan NLS, Zhu MH, Arbuthnot P, Kew M, Clayton MM, Feitelson MA. A cellular gene up-regulated by hepatitis B virus-encoded X antigen promotes hepatocellular growth and survival. Hepatol 2001; 34: 146-157
6. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 385-392
7. Qin LL, Su JJ, Li Y, Yang C, Ban KC, Yian RQ. Expression of IGF-II, p53, p21 and HBxAg in precancerous events of hepatocarcinogenesis induced by AFB1 and/or HBV in tree shrews. World J Gastroenterol 2000; 6: 138-139
8. Murakami S. Hepatitis B virus X protein: A multifunctional viral regulator. J Gastroenterol 2001; 36: 651-660
9. Diao J, Garces R, Richardson CD. X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis. Cytokine Growth Factor Rev 2001; 12: 189-205
10. Wang XZ, Jiang XR, Chen XC, Chen ZX, Li D, Lin JY, Tao QM. Seek protein which can interact with hepatitis B virus X protein from human liver cDNA library by yeast two-hybrid system. World J Gastroenterol 2002; 8: 95-98
11. Kong HJ, Hong SH, Lee MY, Kim HD, Lee JW, Cheong JH. Direct binding of hepatitis B virus X protein and retinoid X receptor contributes to phosphoenolpyruvate carboxykinase gene transactivation. FEBS Lett 2000; 483: 114-118
12. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317-320
13. Slagle BL, Lee TH, Medina D, Finegold MJ, Butel JS. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol Carcinog 1996; 15: 261-269
14. Staib F, Perwez Hussain S, Hofseth LJ, Wang XW, Harris CC. TP53 and liver carcinogenesis. Hum Mutat 2003; 21: 201-216
15. Pollicino T, Terradillos O, Lecoueur H, Gougeon ML, Buendia MA. Pro-apoptotic effect of the hepatitis B virus X gene. Biomed Pharmacother 1998; 52: 363-368
16. Xu ZH, Zhao MJ, Li TP. P73 beta inhibits transcriptional activities of enhancer I and X promoter in hepatitis B virus more efficiently than p73alpha. World J Gastroenterol 2002; 8: 1094-1097
17. Kang-Park S, Lee JH, Shin JH, Lee YI. Activation of the IGFII gene by HBV-X protein requires PKC and p44/p42 map kinase signalings. Biochem Biophys Res Commun 2001; 283: 303-307
18. Arbuthnot P, Capovilla A, Kew M. Putative role of hepatitis B virus X protein in hepatocarcinogenesis: Effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. J Gastroenterol Hepatol 2000; 15: 357-368
19. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365
20. Takehara T, Hayashi N. Fas and Fas ligand in human hepatocellular carcinoma. J Gastroenterol 2001; 36: 727-728
21. Ibuki N, Yamamoto K, Yabushita K, Okano N, Okamoto R, Shimada N, Hakoda T, Mizuno M, Higashi T, Tsuji T. In situ expression of Granzyme B and Fas-ligand in the liver of viral hepatitis. Liver 2002; 22: 198-204
22. Natoli G, Ianni A, Costanzo A, De Petrillo G, Ilari I, Chirillo P, Balsano C, Levrero M. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 1995; 11: 1157-1164
23. Paterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatol 1995; 21: 313-321
24. Han J, Yoo HY, Choi BH, Rho HM. Selective transcriptional regulations in the human liver cell by hepatitis B viral X protein. Biochem Biophys Res Commun 2000; 272: 525-530
25. Shiota G, Oyama K, Udagawa A, Tanaka K, Nomi T, Kitamura A, Tsutsumi A, Noguchi N, Takano Y, Yashima K, Kishimoto Y, Suou T, Kawasaki H. Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a Japanese population: Involvement of HBx and p53. J Med Virol 2000; 62: 151-158
26. Niitsuma H, Ishii M, Miura M, Kobayashi K, Toyota T. Low level hepatitis B viremia detected by polymerase chain reaction accompanies the absence of the HBe antigenemia and hepatitis in hepatitis B virus carriers. Am J Gastroenterol 1997; 92: 119-123
27. Carman WF. S gene variation of HBV. Acta Gastroenterol Belg 2000; 63: 182-184
28. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99: 403-413
29. Roskans T, Libbrecht L, Damme BV, Desmet V. Fas and Fas ligand: Strong co-expression in human hepatocellular carcinoma; Can cancer induce suicide in peritumoural cells? J Pathol 2000; 191: 150-153
30. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinoma. Proc Natl Acad Sci U S A 1997; 94: 6420-6425
31. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR. Lyphocyte apoptosis induced by CD95(APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion? Nat Med 1996; 2: 1361-1366
32. O'Connell J, Houston A, Bennett MW, O'Sullivan GC, Shanahan F. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 2001; 7: 271-274
33. Restifo NP. Countering the 'counterattack' hypothesis. Nat Med 2001; 7: 259.
34. Ito Y, Monden M, Takeda T, Eguchi H, Umeshita K, Nagano H, Nakamori S, Dono K, Sakon M, Nakamura M, Tsujimoto M, Nakahara M, Nakao K, Yokosaki Y, Matsuura N. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Canner 2000; 82: 1211-1217
35. Fukuzawa K, Takahashi K, Furuta K, Tagaya T, Ishikawa T, Wada K, Omoto Y, Koji T, Kakumu S. Expression of fas/fas ligand(fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC). J Gastroenterol 2001; 36: 727-728
36. Shin EC, Shin JS, Park JH, Kim H, Kim SJ. Expression of Fas ligand in human hepatoma cell lines: Role of hepatitis-B virus X (HBX) in induction of Fas ligand. Int J Canner 1999; 82: 587-591
37. Yin XM, Wang K, Cross A, Zhao Y, Zinkel S, Klocke B, Roth KA, Korsmeyer SJ. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999; 400: 886-891
38. Terradillos O, Coste ADL, Pollicino T, Neuveut C, Sitterlin D, Lecoeur H, Gougeon ML, Kahn A, Buendia MA. The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver. Oncogene 2002; 21: 377-386
39. Li J, Xu ZM, Zheng YY, Johnson DL, Ou JH. Regulation of hepatocyte nuclear factor 1 activity by wild-type and mutant hepatitis B virus X proteins. J Virol 2002; 76: 5875-5881
40. Lu B, Wang L, Medan D, Toledo D, Huang C, Chen F, Shi X, Rojanasakul Y. Regulation of Fas (CD95)-induced apoptosis by nuclear factor-kappaB and tumor necrosis factor-alpha in macrophages. Am J Physiol Cell Physiol 2002; 283: C831-838
41. Kasibhatla S, Genestier L, Green DR. Regulation of fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor kappaB. J Biol Chem 1999; 274: 987-992
42. Guo SP, Wang WL, Zhai YQ, Zhao YL. Expression of nuclear factor-kappa B in hepatocellular carcinoma and its relation with the X protein of hepatitis B virus. World J Gastroenterol 2001; 7: 340-344